Single Use Bioreactors Market By Product Type (Stirred Single Use Bioreactors, Bubble Column Single Use Bioreactors, Wave-Mixed Single Use Bioreactors), By Application (Biopharmaceutical, Biotechnology, Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
22831
-
June 2023
-
168
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Report Overview
Single Use Bioreactors Market size is expected to be worth around USD 15.4 Bn by 2032 from USD 3.9 Bn in 2022, growing at a CAGR of 15.1% during the forecast period from 2023 to 2032.
The Single-Use Bioreactors Market is of the utmost importance, as it is one of the most rapidly expanding sectors in the extensive biotechnology landscape. This cutting-edge technology has effectively ushered in a major transformation in the field of bioprocessing, providing an economically viable and highly adaptable solution for the development and production of biologics. In addition to a growing demand for biologics and a reduction in operational costs, the adoption of single-use technologies is also on the rise, which are the primary factors driving this remarkable progress.
Single-Use Bioreactors are complex systems designed to facilitate the cultivation of cells and microbes. The primary benefit of these bioreactors is their disposability, which eliminates the need for sterilization and cleaning procedures. In the production of biologics, including vaccines, gene therapies, and monoclonal antibodies, this revolutionary technology is indispensable. Single-Use Bioreactors have the potential to revolutionize the field of bioprocessing by increasing adaptability, reducing costs, and mitigating the risks of cross-contamination.
In the field of biopharmaceutical manufacturing, single-use bioreactors have received widespread acclaim due to their numerous advantages. Traditional stainless steel bioreactors are rendered obsolete as a result of the elimination of complex cleansing, sterilization, and validation procedures. The combination of the simplification of workflow, the resultant process optimization, and the concurrent reduction in the need for elaborate infrastructure augments operational efficiency. Single-use bioreactors' disposability increases product safety while concurrently mitigating the risk of batch-to-batch variances, thereby ensuring consistent and reliable production.
From the domain of single-use bioreactors have emerged an abundance of remarkable innovations. The introduction of cutting-edge sensor technologies that enable real-time monitoring and control of crucial process parameters, such as pH, dissolved oxygen, and temperature, is the most significant of these innovative developments. In addition, the advancement of materials and design paradigms has resulted in significant improvements in the scalability and performance of single-use bioreactors, enabling the attainment of larger and more efficient production capacities.
The market for bioreactors designed for single use has expanded significantly. Demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and cell therapies, has accelerated the adoption of single-use bioreactors in manufacturing processes to unprecedented levels. The pervasive use of single-use bioreactors is evident in the research and development, experimental scale production, and large-scale commercial manufacturing sectors. Future projections indicate that the market will continue its ascent as an increasing number of biopharmaceutical companies recognize the numerous benefits of single-use bioreactors and direct their investments toward their seamless implementation.
Driving Factors
Increasing Demand for Biologics and Biosimilars
The global increase in the incidence of chronic diseases has fuelled a surge in demand for biologics and biosimilars. As a result, there has been a notable increase in research and development related to these products, resulting in greater adoption of single-use bioreactors.
The demand for personalized medicine and targeted therapies is increasing
Increasing demand for personalized medicine and targeted therapies has accelerated the adoption of single-use bioreactors. These bioreactors offer superior scalability and usability, making them the technology of choice for developing new medicines. Consequently, small and medium-sized biopharmaceutical companies are adopting single-use technologies at an increasing rate.
Expansion of the biopharmaceutical industry in emerging markets
The expanding biopharmaceutical industry in emerging markets has significantly increased the demand for single-use bioreactors. These markets are experiencing accelerated growth, resulting in an increase in demand for healthcare products, especially biologics and biosimilars. Consequently, research and development expenditures have increased, propelling the market growth for single-use bioreactors.
A Favorable Regulatory Environment
A favorable regulatory environment within the biopharmaceutical industry has facilitated the adoption of single-use bioreactors. This regulatory support has fostered a competitive environment favorable to manufacturers in this market.
Potential Disruptors
The competitive landscape of the Single-Use Bioreactors Market could be affected by potential market disruptors despite the market's robust growth. Emerging technologies that offer greater efficacy or cost savings may present a difficulty. Changes in regulations, particularly regarding environmental concerns associated with the disposal of single-use products, could also have an effect on the market.
Adapting to Environmental Consciousness
The market may be affected by a transition toward eco-friendly products. To accommodate evolving consumer preferences, manufacturers should consider sustainable practices and develop biodegradable or recyclable materials.
Continuous Innovation
To remain competitive, companies need to prioritize continuous innovation. It is essential to remain vigilant and responsive to altering consumer and regulatory demands. Embracing emerging technologies and integrating them into designs for single-use bioreactors can help meet changing market demands.In the Single Use Bioreactors Market, the adoption of mammalian cell fermentation technology is driving scalability, flexibility, and reduced contamination risks.
Restraining Factors
Limited Capacity of Single-Use Bioreactors Compared to Stainless Steel Bioreactors
Compared to conventional stainless steel bioreactors, single-use bioreactors have a limited capacity. The size restriction presents an obstacle for large-scale production activities that demand high production volumes. While single-use bioreactors are restricted to a certain volume, stainless steel bioreactors can be made to accommodate any capacity. This limitation has made it difficult for single-use bioreactors to compete with conventional stainless steel bioreactors in large-scale production activities.
Concerns Regarding the Quality and Consistency of Single-Use Bioreactor Components
Concerns regarding the quality and consistency of single-use bioreactor components are another factor restraining the adoption of single-use bioreactors. Plastics and films are used to create the components of single-use bioreactors, whose quality and consistency can vary. The materials used in single-use bioreactors are also susceptible to degradation, which can compromise the integrity of the product. To address these issues, stringent quality control measures must be implemented throughout the entire supply chain, from production to disposal.
Limited Availability of Specialized Single-Use Bioreactor Products
Utilizing single-use bioreactors necessitates the availability of specialized products. These products consist of disposable sensors, tubes, containers, and filters. Due to their limited availability, single-use bioreactors face significant obstacles in their widespread adoption. These products can also be prohibitively expensive.
High Initial Costs Associated with the Adoption of Single-Use Bioreactors
Single-use bioreactors have a high initial cost associated with their adoption. Single-use bioreactors can offer long-term savings due to their quick setup times and low operating costs, but their high initial cost can be a hindrance. The high price is due to the required specialized apparatus, which includes disposable sensors, tubes, bags, and filters.
Limited Compatibility of Single-Use Bioreactors with Certain Cell Lines and Culture Conditions
Lastly, single-use bioreactors' compatibility with particular cell lines and cultivation conditions can be a major limiting factor. The design of single-use bioreactors is optimized for specific culture conditions, which can limit their compatibility with particular cell lines. Foaming can be an issue with single-use bioreactors, leading to unstable culture conditions.
Product Type Analysis
The stirred-tank bioreactors and single-use bioreactors product categories are used to segment the Single-Use Bioreactors Market. The segment of stirred-tank bioreactors dominates the market. The pervasive adoption of these bioreactors in the biopharmaceutical industry is due to their adaptability, scalability, and high efficiency. In addition, they provide continuous operation and optimal energy utilization, reducing overall operational costs.
The economic growth of emerging nations has had a significant impact on the biopharmaceutical industry's adoption of stirred-tank bioreactors. These nations have experienced robust development in the biopharmaceutical industry, which has increased demand for stirred-tank bioreactors. Increasing investments in research and development have also contributed to the expansion of this market segment.
Due to their numerous benefits, the consumer trend and behavior toward stirred-tank bioreactors have been positive. The majority of biopharmaceutical firms choose these bioreactors to assure product quality, greater efficiency, and cost-effectiveness. In addition, the adaptability and scalability of these bioreactors have made them popular with small and medium-sized biotechnology companies.
Cell Type Analysis
Because they are widely used in the production of biologics, the Mammalian Cells Segment dominates the Single-Use Bioreactors Market. Numerous therapeutic proteins, monoclonal antibodies, and vaccines are produced using mammalian cells. Single-use bioreactors offer numerous benefits, including usability, scalability, and cost-effectiveness, making them the optimal choice for mammalian cell culture applications.
In addition to influencing the adoption of mammalian cells in the Single-Use Bioreactors Market, the economic growth of emerging economies has also had an effect. These nations have experienced robust development in the biopharmaceutical industry, which has increased the demand for mammalian cell culture applications. Government and private sector investments in the biopharmaceutical industry have also contributed to the expansion of this market segment.
Due to their pervasive use in the production of biologics, the consumer attitude and behavior toward mammalian cells have been positive. The majority of biopharmaceutical companies choose single-use bioreactors to assure product quality, increased efficiency, and cost-effectiveness. In addition, the scalability and adaptability of these bioreactors have made them popular with small and medium-sized biotechnology companies.
Application Analysis
Due to the rising demand for biologics and rising investments in biopharmaceutical research and development activities, the Biopharmaceuticals Segment dominates the Single-Use Bioreactors Market. Biopharmaceuticals are composed of extremely complex molecules that necessitate precise manufacturing processes to ensure their quality and efficacy. Single-use bioreactors offer numerous benefits, including adaptability, scalability, and cost-effectiveness, making them an ideal choice for biopharmaceutical production.
The economic growth of emerging societies has also had an effect on biopharmaceutical adoption. These economies have experienced robust development in the biopharmaceutical industry, resulting in a rise in demand for single-use bioreactors. Government and private sector investments in the biopharmaceutical industry have also contributed to the expansion of this market segment.
As a result of their greater efficacy and specificity compared to conventional small-molecule therapeutics, the consumer trend and behavior toward biopharmaceuticals has been positive. To ensure the integrity and efficacy of their products, the majority of biopharmaceutical companies choose single-use bioreactors. In addition, the scalability and adaptability of these bioreactors have made them popular among small and medium-sized biotech companies.
Key Market Segments
By Product Type
- Stirred
- Bubble Column
- Wave-Mixed
By Cell Type
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
- Other
By Molecule Type
- Monoclonal Antibodies (Mabs)
- Vaccines
- Stem Cells
- Gene-Modified Cells
- Other
By Application
- Biopharmaceutical
- Biotechnology
- Others
Growth Opportunity
Growing demand for gene therapies and cell-based therapies
The rapid development of gene therapies and cell-based therapies has substantially increased the demand for bioreactor technology that is more adaptable and scalable. Single-use bioreactors are the optimal choice for these emerging therapies, as they enable more rapid and adaptable cell culture production.
Increasing adoption of single-use bioreactors in small and mid-sized biopharmaceutical companies
Small and mid-sized biopharmaceutical companies are increasingly adopting single-use bioreactors due to their lower initial investment, quicker turnaround times, and lower operational costs. This presents a substantial market opportunity for bioreactor manufacturers who can produce high-quality, dependable systems.
Expansion of the Biopharmaceutical Industry in Emerging Markets
The accelerated growth of the biopharmaceutical industry in emerging markets presents a tremendous opportunity for businesses that can provide flexible and scalable bioreactor technology. Single-use bioreactors are ideally adapted for these markets due to their lower initial investment, quicker turnaround times, and lower operating expenses.
Increasing investments in research and development of biologics and biosimilars
As the biopharmaceutical industry continues to expand, there is a rising demand for the development of novel and cutting-edge therapies. This necessitates substantial investments in the research and development of biologics and biosimilars, which increases the need for more efficient and dependable bioreactor technology.
Improved Automation and Monitoring Capabilities
Integration with sophisticated automation and monitoring systems is one of the most significant benefits of single-use bioreactors. This enables more precise control of key parameters such as temperature, pH, and dissolved oxygen, resulting in more consistent and superior cell cultures.
Latest Trends
Increasing Use of Single-use Bioreactors in the Production of Vaccines
Due to their benefits, which include increased operational efficiency, cost-effectiveness, and decreased risk of contamination, single-use bioreactors are increasingly used in the production of vaccines. Compared to conventional stainless steel bioreactors, which require routine cleaning and sterilization, single-use bioreactors allow for rapid process alterations. Vaccine manufacturers have also benefited from the scalability of single-use bioreactors, which has allowed for the rapid production of vaccines in response to pandemics or epidemics.
Growing Interest in the Development of Single-Use Bioreactors for Stem Cell Production
Due to their capacity to support stem cell growth and differentiation, the development of single-use bioreactors for stem cell production has gained momentum in recent years. By using single-use bioreactors, manufacturing processes can be made more efficient and cost-effective. Stem cells have the potential to treat numerous life-threatening diseases. In addition, single-use bioreactors have reduced contamination risks, making them suitable for cellular therapies that require highly regulated production processes.
Increasing Adoption of Single-use Bioreactors in the Production of Biosimilars
Single-use bioreactors have become more widely used in recent years for the production of biosimilars, or biologics that are similar to already-approved medications. In the production of biosimilars, the use of single-use bioreactors as opposed to stainless steel bioreactors facilitates faster and more cost-effective biologic manufacturing. In addition, single-use bioreactors provide greater flexibility in the biomanufacturing process because they can be readily scaled up or down based on production needs.
Demand for single-use bioreactors with larger working volumes is increasing
Historically, single-use bioreactors had reduced working volumes, which limited their throughput and, consequently, their use in bioprocessing. However, technological innovation has enabled the development of single-use bioreactors with larger working volumes, resulting in a rise in demand for them. Larger working volume single-use bioreactors provides increased flexibility, quicker turnaround times, and enhanced performance, making them ideal for vaccine and pharmaceutical production.
Regional Analysis
The Single-Use Bioreactors Market is dominated by North America. Every day, new technologies and innovative approaches emerge in the biopharmaceutical industry, which has been advancing rapidly. The region is renowned for its strong emphasis on research and development, the presence of a well-established biopharmaceutical industry, and favorable regulatory policies that encourage the adoption of single-use technologies. These factors have made the market for single-use bioreactors in North America increasingly attractive to biopharmaceutical companies, and the region is expected to dominate the market over the next few years.
The biopharmaceutical industry in North America is one of the main factors that have positioned the region to dominate the single-use bioreactors market. These corporations have established research and development facilities devoted to the creation of innovative therapies for a variety of diseases, including cancer, Alzheimer's, and multiple sclerosis, among others. This not only generates employment opportunities but also provides an ecosystem that sustains the development of the industry, which is essential for the adoption of new technologies such as single-use bioreactors.
Due to the region's regulatory environment, North America is also expected to dominate the market for single-use bioreactors. The United States, Canada, and Mexico, the three most populous nations in the region, have favorable regulatory policies that encourage the adoption of single-use bioreactors in the biopharmaceutical industry. In addition, the regulatory environment in North America is stable, predictable, and innovation-friendly, making the region a secure location for biopharmaceutical industry investments.
In addition, North America's strong emphasis on research and development is a key factor that has positioned the region to dominate the market for single-use bioreactors. The region has state-of-the-art research facilities, institutions of the highest caliber, and research organizations committed to the creation of novel biopharmaceutical products and technologies. This research ecosystem provides crucial support for the development and commercialization of new products, which is essential for the expansion of the biopharmaceutical industry.
In addition, the growing demand for personalized medicine is a major driver for the adoption of single-use bioreactors. Single-use bioreactors are well adapted to the practice of personalized medicine, which tailors medical treatment to an individual's unique genetic makeup. With their ability to produce small quantities of customized drugs, single-use bioreactors are becoming an increasingly popular choice for the production of personalized medicines, making North America an attractive market for biopharmaceutical firms.
Key Regions and Countries
North America
- US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
Thermo Fisher Scientific is an industry leader in the single-use bioreactors market. The company provides an extensive selection of single-use bioreactor systems, including agitated and wave-mixed models. Thermo Fisher's dominant position in the biopharmaceutical industry and commitment to technological innovation contribute to its market dominance.
Sartorius AG is a leading supplier of single-use bioreactors for a variety of applications. The company's product line comprises stirred and wave-mixed bioreactors with advanced control systems, scalability, and dependability. The dedication to innovation and emphasis on producing high-quality products contribute to Sartorius's market position.
Merck KGaA is a global leader in the biopharmaceutical industry for single-use bioreactors. The company offers an extensive selection of bioreactors, including agitated, bubble column, and wave-mixed models. Merck's commitment to research and development, combined with its global presence, positions it as a market leader.
GE Healthcare is a major participant in the single-use bioreactors market, offering a variety of bioreactor systems and consumables. The company's bioreactors are designed to accommodate a variety of applications, including cell culture and fermentation. The bioprocessing technologies expertise and global presence of GE Healthcare contribute to its market competitiveness.
Eppendorf AG is a prominent provider of single-use bioreactors for biopharmaceutical applications. The company offers a variety of bioreactor systems, such as agitated bioreactors with sophisticated control capabilities. Eppendorf's dedication to product innovation, quality, and customer-centricity distinguishes it as a market leader.
Applikon Biotechnology is an industry leader in the provision of single-use bioreactor systems and accouterments. The company provides an extensive selection of agitated bioreactors with sophisticated monitoring and control features. Applikon Biotechnology's market position is bolstered by its emphasis on customer satisfaction, technological advancements, and strong presence in the bioprocessing industry.
Top Key Players in Single-Use Bioreactors Market
- Sartorius Stedim Biotech
- Merck Millipore
- GE Healthcare
- Danaher
- Thermo Fisher Scientific
- Parker Hannifin
- Applikon Biotechnology
- Eppendorf
- Cesco Bioengineering
- Cellexus
- Celltainer Biotech
- PBS Biotech
- Distek
- Solida Biotech
- Pierre Guerin
Recent Development
- In 2020, Sartorius AG, a German biotech equipment and services provider, acquired the dominant stake in kSep Systems, an American single-use bioreactor company. The acquisition is anticipated to strengthen Sartorius' position in the single-use bioreactor market and enable the company to provide its customers with a wider selection of innovative products and services.
- In 2019, GE Healthcare, a subsidiary of General Electric Company and a prominent global provider of medical technologies and services, added the Xcellerex XDR 10 bioreactor to its portfolio of single-use bioreactors. The new product is designed to satisfy the increasing demand for flexible, efficient, and cost-effective solutions in the biotechnology industry.
- In 2018, Merck KGaA, a German multinational pharmaceutical, chemical, and life sciences corporation, acquired Biochrom AG, the foremost manufacturer of single-use bioreactors. The acquisition was part of Merck's plan to expand its biopharmaceutical portfolio and bolster its position in the life sciences industry.
- In 2017, the foremost provider of laboratory equipment and services, Eppendorf AG, introduced the BioBLU 5p single-use bioreactor for microbial fermentation. The product provides scalable, cost-effective, and high-quality solutions for cell culture production, and it has been well-received by the biotechnology industry.
Report Scope
Report Features Description Market Value (2022) USD 3.9 Bn Forecast Revenue (2032) USD 15.4 Bn CAGR (2023-2032) 15.1% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product Type (Stirred, Bubble Column, Wave-Mixed)
By Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, Other)
By Molecule Type (Monoclonal Antibodies (Mabs), Vaccines, Stem Cells, Gene-Modified Cells, Other)
By Application (Biopharmaceutical, Biotechnology, Others)Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; the Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Sartorius Stedim Biotech, Merck Millipore, GE Healthcare, Danaher, Thermo Fisher Scientific, Parker Hannifin, Applikon Biotechnology, Eppendorf, Cesco Bioengineering, Cellexus, Celltainer Biotech, PBS Biotech, Distek, Solida Biotech, Pierre Guerin Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single-User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Sartorius Stedim Biotech
- Merck Millipore
- GE Healthcare
- Danaher
- Thermo Fisher Scientific
- Parker Hannifin
- Applikon Biotechnology
- Eppendorf
- Cesco Bioengineering
- Cellexus
- Celltainer Biotech
- PBS Biotech
- Distek
- Solida Biotech
- Pierre Guerin.